CICC Securities: Maintains Neutral Rating on Shiyao Group (01093.HK) and Lowers Target Price to HK$8.05

Zhixin Finance APP learned that CICC released a research report stating that China Medical Group (01093.HK) has lowered its financial forecast for 2026 and raised it for 2027-28, primarily reflecting a more cautious forecast for the recognition pace of licensing fee income and API revenue. The target price has been lowered to HK$8.05, with the current valuation reasonable (23 times the 2026 P/E ratio), maintaining a neutral rating.